Plecanatide: First Global Approval

20Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Plecanatide (TrulanceTM) is an oral guanylate cyclase-C agonist that is being developed by Synergy Pharmaceuticals for the treatment of gastrointestinal disorders, such as chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a synthetic analogue of human uroguanylin, a 16 amino acid peptide that regulates ion and fluid transport in the gastrointestinal tract. In January 2017, plecanatide received its first global approval in the USA for the treatment of adult patients with CIC. Plecanatide is undergoing phase III investigation in IBS-C. This article summarizes the milestones in the development of plecanatide leading to this first approval in CIC.

Cite

CITATION STYLE

APA

Al-Salama, Z. T., & Syed, Y. Y. (2017). Plecanatide: First Global Approval. Drugs, 77(5), 593–598. https://doi.org/10.1007/s40265-017-0718-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free